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INTRODUCTION 
Tuberculosis remains one of the deadliest communicable diseases of the world with a 
worldwide estimate of 10.4 million new TB cases. Tuberculosis is regarded as one of the 
major health emergencies and is a national priority. In the year 2015 in the south east 
Asian region, number of deaths due to tuberculosis was 1945 per day (equivalent to 9 
passenger planes crashing every day)(1). Tuberculous lymphadenitis is the most common 
manifestation of extrapulmonary tuberculosis. Despite increasing interest in the recent 
years and research advances many immunological aspects of tuberculous lymphadenitis 
remain largely unknown. 
 
The phenomenon of “paradoxical worsening” in which existing lesions worsen or new 
lesions appear was first described by Choremis in 1955 in children with tuberculosis who 
developed transient exacerbation of fever and x-ray changes after initiation of 
antitubercular therapy(2). In fact the first paradoxical reaction may have been observed 
by Robert Koch when he tried to inject large amounts of killed tubercle bacilli in an 
attempt to treat patients with tuberculosis, unsuccessfully, which he termed it as 
“tuberculin shock”(3). It is unpredictable in its timing, severity and duration. A formal 
case definition for Paradoxical reaction (PR) has not been made, but a consensus 
definition for use in clinical and research settings has been used from previous 
prospective studies. This phenomenon requires worsening of symptoms at the same site 
or at an anatomically distant site in the absence of Multidrug resistant (MDR) 
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tuberculosis, poor compliance, impaired digestive absorption, absence of another 
explanation or evidence of treatment failure after an initial improvement on 
antitubercular therapy is noted(4). 
 
This study was designed to define the clinical profile of patients with tuberculous 
lymphadenitis developing paradoxical worsening and to identify possible clinical and 
laboratory predictors for the same. 
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AIMS 
To determine the proportion of Paradoxical reaction in a cohort of patients with 
tuberculous lymphadenitis presenting to a tertiary centre in South India and also to 
identify clinical and laboratory correlates to predict the same. 
 
 
OBJECTIVES 
1. To determine the proportion of patients with tuberculous lymphadenitis developing 
paradoxical worsening 
2. To describe the clinical profile of patients with tuberculous lymphadenitis developing 
paradoxical worsening  
3. To identify possible clinical and laboratory risk factors for development of 
paradoxical reactions in a cohort of patients with tuberculous lymphadenitis.  
12 
 
REVIEW OF LITREATURE 
Paradoxical reaction is an exuberant inflammatory reaction characterized by worsening of 
clinical or radiological findings after initiation of appropriate antitubercular therapy in the 
absence of evidence of drug resistance or presence of an alternative  diagnosis(5). 
Paradoxical worsening in Tuberculosis is a well-known phenomenon seen in HIV 
positive patients after initiation of Anti-retroviral therapy. Case definitions for the same 
in the setting of PLHIV is well described in literature as follows: 
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Adapted from Tuberculosis-associated immune reconstitution inflammatory syndrome: 
case definitions for use in resource-limited settings(6) 
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A formal case definition for paradoxical reaction in non-HIV patients has not been made, 
however a previous study did put forth a criteria which could be adapted to most settings 
however this has not been further validated through large scale trials(7). 
Table 1: DEFINITION OF PARADOXICAL WORSENING –adapted from Geri et al. (7) 
 Paradoxical worsening – Definition 
1. Initial improvement after initiation of antitubercular therapy 
2. Worsening of symptoms at the same site after initial improvement or onset of new 
TB symptoms or signs at a site anatomically distant from previous after initiation of 
antitubercular therapy 
3. Absence of MDR tuberculosis, poor compliance, impaired digestive absorption 
4. Absence of any other explanation for the deterioration 
 
PREVALENCE 
Paradoxical reaction, even though is not well understood, has been described in literature. 
Its prevalence is varied across literature ranging from 5 – 25 % and seems to depend on 
the site of involvement. Cheng et al, found a prevalence of only 2.4% paradoxical 
worsening in pulmonary tuberculosis whereas its prevalence in lymph node tuberculosis 
seems to be higher ranging from 12 – 23 %(7–11).  
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Table 2: Prevalence of Paradoxical Worsening across literature 
 
 Description of article Prevalence of PR 
Smaoui et al(11) Descriptive retrospective study of 
Tuberculous lymphadenitis done in 
Tunisia on a total of 181 patients 
18 (12.1%) 
Cheng SL et 
al(8) 
659 patients with pulmonary tuberculosis 16 (2.4%) 
Cho et al(10) 300 patients with peripheral lymph node 
tuberculosis from medical records 
54 (23%) 
Chahed et al(9) Retrospective study of 501 patients of 
cervical lymphadenopathy over 12 years 
67 (13.4%) 
Hawkeye et 
al(12) 
Retrospective study of 109 patients with 
tuberculous lymphadenopathy 
25(23%) 
Geri et al(7) Single centre retrospective study done a 
76 amongst HIV negative patients with 
Tuberculosis 
19(25%) 
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CLINICAL PRESENTATION OF PARADOXICAL WORSENING 
Natural history of tuberculosis depends on the interaction of the mycobacterium 
tuberculosis and the immune response of the host. The innate immune response contains 
the infection after exposure in 95% of the cases. When reactivation of tuberculosis 
occurs, most hosts can control the ensuing inflammation in an appropriate manner. In 
some cases, an exuberant response is noticed after start of treatment which is termed as 
Paradoxical Worsening(PR). This phenomenon was better recognized in the setting of 
patients living with Human Immunodeficiency virus(PLHIV) after initiation of HAART 
in which setting it is aptly termed immune reconstitution inflammatory syndrome(IRIS). 
Owing to the similar pathogenesis, IRIS and Paradoxical reaction have similar clinical 
manifestations(13).  Leprosy caused by Mycobacterium Leprae, has characteristic 
inflammatory reactions, type I and II, which is distinct and well described after initiation 
of anti Leprae therapy(14). A similar phenomenon can also occur in Mycobacterium 
tuberculosis given the similarity between the organisms in its microbiologic, 
histopathological and clinical characteristics. 
As the definition states, paradoxical worsening in HIV negative individuals can have two 
distinct types of presentation: one that of worsening of pre-existing disease (after an 
initial improvement on antitubercular therapy) and the other being occurrence of disease 
at another site (which was previously not apparently involved). In the former category 
patient develops enlargement of nodes, fluctuation, tenderness, abscess and fistula 
formation. The latter category presents as lymph nodal enlargement at another site or 
involvement of lung, pericardium, pleura, peritoneum, spine, brain, liver, ovary, psoas 
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muscle, paravertebral muscle and eye. Campbell and Dyson  studied 108 patients with 
lymph node tuberculosis treated with contemporary appropriate treatment and were noted 
to have developed paradoxical worsening manifested as follows appearance of new 
lymph nodes(12%), enlargement of pre-existing lymph nodes(13%) and new onset 
fluctuation of nodes(11%)(4). Hawkeye et al, did a retrospective analysis of 109 patients 
with Tuberculous Lymphadenitis (most common site of involvement was cervical) and 
paradoxical worsening occurred in 27 (23%) patients. Median time to occurrence of 
paradoxical worsening was 46 days (10 – 405 days) and 17 patients(68%) had 
enlargement of pre-existing nodes, 9 patients(36%) had development of new nodes and 1 
each developed lung consolidation, perforated viscus and pericardial effusion(12). 
Chahed et al, performed a retrospective study amongst 501 patients diagnosed with 
peripheral cervical lymph node tuberculosis in a tertiary teaching institute in Tunisia. 
Paradoxical reaction occurred in 67 patients (13.4%) with a median time to onset of 7 
months (4 – 9 months). Of these 44.8% had worsening at the previous lymph node site, 
new lymph nodes appeared in 32.8% patients, fluctuation and fistula formation occurred 
in 16.4% and 6% patients(9). These studies provide information regarding the type of 
clinical presentation described in literature for paradoxical worsening in the form of 
worsening of pre-existing lymph node, recruitment of new sites and involvement of other 
organ systems. 
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Table 3: Time to Paradoxical Worsening 
 
 Description of article Median time to onset 
Days (IQR) 
Cheng SL et 
al(8) 
659 patients with pulmonary 
tuberculosis 
26 days(3 – 100 days) 
Cho et al(10) 300 patients with peripheral lymph 
node tuberculosis from medical records 
8 weeks( 4- 14 weeks) 
Chahed et al(9) Retrospective study of 501 patients of 
cervical lymphadenopathy over 12 
years 
7 months (4 – 9 months) 
Hawkeye et 
al(12) 
Retrospective study of 109 patients 
with tuberculous lymphadenopathy 
46 days(21 – 139 days) 
Geri et al(7) Single centre retrospective study done a 
76 amongst HIV negative patients with 
Tuberculosis 
86 days(36 – 125 days) 
 
Usually outcomes in paradoxical worsening tends to be excellent especially in lymph 
nodal tuberculosis, however that’s not the case in miliary tuberculosis and CNS 
tuberculosis. Patients with miliary tuberculosis can present with ARDS. Patients with 
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CNS tuberculosis could present with cerebral tuberculomas, hydrocephalus, 
opticochiasmal tuberculosis and arachnoiditis(15–19). Patients can present with pleural 
effusion as a manifestation of paradoxical worsening with anecdotal reports of 
chylothorax secondary to mediastinal adenopathy(20). Cheng et al, identified 122 
episodes of paradoxical worsening, of which 101(82.8%) occurred in extrapulmonary 
tuberculosis. Median duration to occurrence of paradoxical worsening was 60 days. 60 
episodes occurred in Central nervous system(21).  
PREDICTORS FOR PARADOXICAL WORSENING 
Undoubtedly, HIV positive status has the greatest association with the occurrence of 
paradoxical worsening. An HIV positive patient has a 5 times greater odd of developing 
paradoxical worsening than in non-HIV patient(22). Risk factors for paradoxical reaction 
in non-HIV patients have been few and described inconsistently. 
With the rising incidence of drug resistant tuberculosis, one of the major differential 
diagnosis considered in the setting of paradoxical worsening is MDR/XDR Tuberculosis. 
Although an immunopathological mechanism is elucidated, no reliable and rapid 
diagnostic test is available for its diagnosis. Paradoxical worsening is a diagnosis of 
exclusion after ruling out drug resistant tuberculosis, drug noncompliance, poor drug 
absorption and other alternative diagnoses (Sarcoidosis, Lymphoma, Fungal infections). 
As mentioned above, paradoxical worsening usually gets misdiagnosed as drug resistant 
tuberculosis resulting in unnecessary institution of toxic second line anti-tubercular 
drugs. Hence being able to predict and diagnose paradoxical worsening is of utmost 
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importance as this phenomenon can be managed with continuation of antitubercular 
therapy, steroids and anti-inflammatory drugs. 
 
Most of the predictors described in literature are based on the current understanding of 
the immunopathogenesis of this phenomenon. It is proposed that at the onset of the 
disease there is a relative immunodeficiency at the biological level which gets corrected 
with treatment resulting in this immune phenomenon. Predictors which suggest the initial 
immunodeficient state include positive AFB smear (suggesting heavy bacillary load), low 
baseline absolute lymphocyte count, anemia and negative tuberculin skin test. This is a 
direct corollary from Immune Reconstitution Inflammatory Syndrome as described in 
HIV infected patients on Combined Anti-retroviral Therapy in the early phase of 
tuberculosis (<2 weeks) when the bacillary load is higher. Other studies have found 
hypoalbuminemia and elevated baseline monocyte count as a predictor of paradoxical 
worsening(12,23,24). Similarly it’s been seen that patients with CSF smears which were 
positive for bacilli develop CNS related paradoxical worsening like cerebral 
tuberculomas, opticochiasmal disease and arachnoiditis(25,26).In contrast to increased 
predilection for conditions with high bacillary load, this phenomenon is seen more in 
extrapulmonary disease which is classically paucibacillary(24).  In the setting of 
peripheral lymphadenopathy there is antigenic persistence in these anatomic sites which 
could explain its occurrence(13). 
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Paradoxical worsening seems to be more common among patients with lymph node 
tuberculosis and is the most common extra-pulmonary form. As evidenced by Geri et al, 
out of the 76 patients with tuberculosis, there were 19 episodes of paradoxical worsening, 
About 72% of cases, were tuberculous lymphadenitis, with PR seen in 13 (68%) of these 
cases. Thus it seemed that lymph node tuberculosis commonly resulted in paradoxical 
worsening(7). Risk factors for development of paradoxical worsening included low 
absolute lymphocyte count (<1000/mm3) and anemia(<10.5 g/dl)(7).  Cheng et al, 
similarly identified extrapulmonary involvement at initial diagnosis, lower baseline 
lymphocyte count and greater surge in lymphocyte counts as independent risk factor for 
paradoxical worsening(24). In another study done in 2007, lower baseline absolute 
lymphocyte counts and anemia were again identified as risk factors in addition to low 
body mass index and  hypoalbuminemia(8). Cho et al found younger age, male gender 
and tenderness at the time of diagnosis as independent risk factor for paradoxical 
worsening(10).On the other hand, Chahed et al, identified lymph node size of >3cm and 
presence of extra-lymph nodal tuberculosis as independent risk factors for development 
of paradoxical worsening(9). 
Risk factors seem to be different in patients with other forms of tuberculosis, however it 
seems to follow a pattern which stems from the basic pathogenesis of the disease -
immunorestitution. In a retrospective study done in South-Korea amongst patients with 
139 patients with pleural tuberculosis, 32(23%) patients developed paradoxical 
worsening. Risk factors identified included younger age, high serum albumin, low 
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proportion of lymphocyte and high proportion of PMN in pleural fluid(23). In another 
retrospective cohort study done in South Korea amongst 458 patients with isolated 
pleural tuberculosis, paradoxical worsening occurred in 72 patients(16%) with a mean 
time of development of 8.8 +/- 6.4 weeks, development of paradoxical worsening was 
independently associated with proportion of eosinophils and protein concentrations in 
pleural fluid(27). Prospective and retrospective data were collected on TB patients from 
four UK centres between 1999 and 2008. Of the 1817 patients with tuberculosis, 82 
(4.5%) patients developed paradoxical worsening. Frequency was higher among HIV 
positive(14.4%) than among HIV negative patients(3.8%). This study showed that HIV 
positive status is the greatest independent risk factor for development of Paradoxical 
worsening(OR=5). Other risk factors identified included a positive mycobacterial culture 
and Nucleic acid amplification technique, lack of non HIV immunosuppression, alcohol 
consumption, smoking, raised baseline ESR and presence of initial disease at 
extrathoracic lymph nodes. Lymph node disease and positive TB culture had an increased 
odds of 64.33  and 6.87 fold respectively(22). 
 
At the time of diagnosis of paradoxical worsening there is a surge in the absolute 
lymphocyte count, inflammatory markers like Erythrocyte Sedimentation Rate and C-
Reactive Protein and a change in the tuberculin anergy status from negative to positive. 
All these findings suggest immune restitution as the mechanism for this phenomenon. 
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Table 4: Predictive factors described in literature 
 
Younger age(10,12) 
Male sex(10,12) 
Lymph nodal tuberculosis(22) 
Lymph node size > 3cm(9) 
Tenderness of lymph node at the time of diagnosis(10) 
Associated extra-lymph nodal tuberculosis(9,24,28) 
Lymphopenia at baseline(8) 
Greater change in Lymphocyte count(8) 
Elevated baseline monocyte count(12) 
Anemia(8) 
Hypoalbuminemia(8) 
Positive TB culture(22) 
 
PATHOGENESIS 
A precise pathogenesis model has not been developed for paradoxical worsening. Most of 
our understanding regarding paradoxical worsening comes from indirect measures like 
tuberculin sensitivity testing and change in laboratory parameters. At the crux of the 
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pathogenesis is the phenomenon of immune restitution which comes from the 
understanding that paradoxical worsening belongs to the spectrum of immune 
reconstitution inflammatory syndrome(29). Evidence of a change in the immune status of 
the patient while on antitubercular therapy has been consistently proven. Tuberculin test 
has been found to be negative in patients who are severely ill or hypoproteinemic with 
reversal of test status after appropriate nutritional supplementation within 2 weeks(30). 
Similarly, it has been found that patients who develop paradoxical reaction have a 
negative tuberculin test due to advanced disease at the initiation of therapy which 
becomes positive after a few weeks of initiation of therapy(31). All these point towards a 
possibility of immunorestitution, in the pathogenesis of paradoxical worsening. Other 
theory is that of hypersensitivity to the mycobacterial antigens released after initiation of 
anti-tubercular therapy like that of a Type II Lepra reaction. Lipoarabinomannan, a 
protein from the cell wall of M.Tuberculosis has been implicated in this hypersensitivity 
reaction by causing the release of TNFα from mononuclear phagocytes. In fact patients 
who develop paradoxical TB IRIS have higher pretreatment levels of 
lipoarabinomannan(13).   
ROLE OF IMMUNORESTITUTION IN PARADOXICAL WORSENING 
T cells can be classified into T Helper cells and T cytotoxic cells. T helper cells can be 
further classified based upon the profile of cytokines secreted by them into T helper 1 and 
T helper 2 cells(32). T helper 1 cells secrete Interferon (IFN) – γ and Interleukin (IL) – 2 
whereas Th2 cells produce IL-4, IL-5, IL-6, IL-10 and IL-13. T helper 1 cells are 
responsible for the cell mediated immunity and T helper 2 cells are responsible for 
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humoral immunity and allergic responses. In addition, the cytokines produced by a T 
helper subset seems to propagate the production of the same subset and inhibit the 
production of the other Th subset. Differentiation of T helper cells into each of these 
subsets depends on the cytokine microenvironment. For instance, the presence of IL-12 
secreted by macrophages, results in differentiation of T helper cells into T helper 1 cells 
and production of IFN-. On the contrary presence of IL-4 results in differentiation of T 
helper cells into T helper 2 cells. The cytokines produced by Th1 subset seems to be pro-
inflammatory whereas cytokines produced by Th2 subset seems to be anti-
inflammatory(33,35,36). Th1 response even though is pro-inflammatory is microbicidal 
in contrast to the Th2 response. In the presence of excess of Th2 response, the 
microbicidal response of Th1 is suppressed as explained above. In active tuberculosis, it 
has been found that at the outset there is a Th2 predominant response which shifts to a 
Th1 predominant response. This was clearly established it was found that PPD stimulated 
PBMCs in active pulmonary TB at the time of diagnosis have depressed production of 
immunoprotective cytokines – IFNγ and IL-2 which are essential to contain 
Mycobacterial infection and to form functional granulomas. Instead there is increased 
production of immunosuppressive and macrophage deactivating cytokines – IL-10 and 
TGF β(34). This Th2 predominant response is responsible for the tuberculin anergy in 
some of the patients with active tuberculosis, as evidenced by the increased levels of IL-4 
and IL-10 and lower levels of IL-12 positive cells in the subset of patients with negative 
tuberculin test(31). Undoubtedly, the immune response which predominate at the onset of 
the disease in active tuberculosis is a Th2 response(35).  
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As the treatment progresses it has been found that the cytokines expressed by the Th2 
response, TGFβ and IL-10, progressively decline(34). At the same time, previously 
negative tuberculin skin test become positive, in other words the balance of the immune 
response shifts to the Th1 arm. This would result in release of proinflammatory cytokines 
resulting in worsening of lymph nodes, lung lesions, occurrence of pleural effusion, 
tuberculomas, hydrocephalus(36).  
This transition from Th2 to Th1 response happens in all patients who have developed 
active tuberculosis. The reason why a patient with active tuberculosis is unable to contain 
the infection is due to the Th2 predominant response rather than the Th1 predominant 
response. Various factors that have been considered to be responsible for this polarization 
could be the age, host genetics, cytokines in the microenvironment,  the type, dose and 
localization of antigens, type of antigen presenting cells,  co-stimulatory molecules(37).  
Thus, immune recovery is the norm in patients being treated for tuberculosis. The 
exactness and appropriateness of the immune recovery determines whether the patient 
develops paradoxical worsening. An overwhelming immunorestitution would result in a 
more severe paradoxical worsening. Thus, the degree of paradoxical worsening would 
depend on the initial immunological state of the patient and the overall balance of the 
pro-inflammatory and anti-inflammatory cytokines.  
Even though it is well described that Th2 to Th1 transition occurs in patients with 
tuberculosis, it has never been conclusively established, to what happens to the Th1 
response which the patient has developed during the treatment. Does it persist till the 
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completion of therapy? Does it change over to an anti-inflammatory Th2 later? Future 
research must also emphasise on elucidating this part of the pathogenesis.  
ROLE OF T Regulatory cells in the Immunopathogenesis of Tuberculosis and Its Role in 
Paradoxical Worsening 
Pathogenesis of Tuberculosis can be described as chronic persistent antigenic stimulation, 
which maintains a sustained immune response against the bacilli but fails to eradicate the 
same. This immune response does have a regulatory component to it which has been well 
elucidated off late. This regulatory function is mediated by a subset of CD4 cells – 
CD4+CD25+ regulatory cells which inhibits the actions of CD4 and CD8 cells. They 
were initially described in relation to self-tolerance and prevention of autoimmune 
conditions. They have been described with chronic infections like tuberculosis too. 
Specific function of Regulatory T Cells is suppression of specific immune response 
produced by the T helper 1 cells. This is evidenced by the demonstration of increased 
expression of IFNγ, a T helper 1 marker, on suppression of regulatory T cell 
expression(38,39). Thus, suppression of these cells may play a role in the 
immunopathogenesis of paradoxical response, however there is no conclusive evidence 
for the same. There has been indirect evidence of its role based on the effect of vitamin D 
status of the body and occurrence of paradoxical worsening. Vitamin D has been found to 
have an anti-inflammatory effect by promoting FoxP3 and CTLA4, which are markers of 
regulatory T cells(40).  
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Figure 1: Subdivisions of the T helper response and its respective functions, Adapted from 
IL-6 biology: implications for clinical targeting in rheumatic disease(41) 
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Figure 2: T helper response effector response (adapted from berger et al)(33) 
 
HYPERSENSITIVITY TO MYCOBACTERIAL ANTIGENS 
Another important cytokine known to play an important role in the immunopathogenesis 
of tuberculosis is TNFα. TNFα is secreted by macrophages and monocytes in response to 
Mycobacterium tuberculosis. It was seen that live mycobacterium was able to trigger the 
release of TNFα(42). In 1989, lipoarabinomannam, mycobacterial cell wall glycolipid, 
was reported to stimulate the release of TNFα from human and murine macrophages(43). 
Another important antigen implicated in the stimulation of TNFα is 30 kDa α 
antigen(44). The role of TNFα is further elucidated from reports of increased occurrence 
of paradoxical worsening in patients who develop tuberculosis while on treatment with 
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TNFα blockers, after stopping TNFα blockers(45,46).TNFα plays a major role in the 
pathogenesis of tuberculosis: 
1) TNFα promotes apoptosis of mycobacteria infected cells 
2) TNFα promotes the maturation of dendritic cells which in turn activates the cellular 
immunity 
3) TNFα increases the antimicrobial activity of macrophages 
4) TNFα plays a major role in the recruitment of monocytes and antigen specific T 
lymphocytes(47) 
5) TNFα is critical in the formation and maintenance of granuloma complex(48,49) 
6)Promotion of central caseation which promotes mycobacterial persistence within the 
granuloma(50) 
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Figure 3: Role of TNFα in the pathogenesis of Tuberculosis, adapted from Immunological 
control of tuberculosis: role of tumour necrosis factor and more, S Stenger(47) 
 
Thus, TNFα plays a major role in the inflammatory reaction of paradoxical worsening 
and thus, can be a potential target for treatment as described in the treatment section of 
this dissertation.  
TREATMENT OPTIONS 
There are no definite guidelines for treatment of Paradoxical worsening. Treatment 
options available are based on the understanding that this phenomenon is an exaggerated 
immune response after initiation of appropriate antitubercular therapy. Hence treatment 
described in literature aims at curbing this hyperactive immune response. Treatment 
options available in lymph nodal tuberculosis with paradoxical worsening include: 
surgical management and medical management. Surgical management could range from 
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a mere aspiration of pus from the lymph node of concern to extensive debridement of the 
lymph node and sinuses. This could serve as both a therapeutic measure as well as 
diagnostic measure to rule out resistance and alternative diagnosis. 
Surgical management of Paradoxical Worsening of Tuberculous Lymphadenitis 
Traditionally, role of surgery, in a case of tuberculous lymphadenitis is limited to 
histopathological and microbiological diagnosis. However, in the case of paradoxical 
worsening it has been found that removal of the site of inflammation, would result in 
resolution of symptoms. This is applicable for patients who does not respond to the 
medical treatment or the disease is extensive or patient has extensive discharging sinuses. 
A retrospective chart review of patients referred for surgical relief of symptom, had 6 
patients with discharging sinus and were on antitubercular therapy for at least 3 months. 
Amongst these 14 patients, 10 underwent lymph node excision, 3 underwent excision 
along with incision and drainage of cold abscesses and 1 patient underwent incision and 
drainage with debridement(51).  
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Table 5: Surgical Management of patients with paradoxical worsening adapted from 
gaikwad et al(51) 
 
Age (Mean) 26.1 (Range: 15 – 40) 
Sex (Male: Female) 1:13 
Presentation: 
a. Swelling 
b. Sinus 
c. Constitutional Symptoms 
d. Disseminated  
 
a. 14 (100%) 
b. 6(42.9%) 
c. 6(42.9%) 
d. 3(21.3%) 
Mean duration of symptoms 6.8 months 
Mean duration of Antitubercular Therapy 7.4 (Range: 3 – 15) months 
Surgical Procedures performed 
a. Lymph node excision 
b. Lymph node excision with Incision 
and drainage  
c. Incision and drainage with 
debridement 
 
a. 10 
b. 3 
 
c. 1 
Types of Lymphadenectomy 
a. >1 lymph node level excised 
 
a. 5 
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b. Single Level excised  b. 9 
 
Surgical approach was used in 71.6% of patients with Paradoxical worsening in a 
retrospective study done in Tunisia(9). Surgical excision of fluctuant lymph nodes, 
abscesses and sinuses could shorten the duration of antitubercular therapy, give 
symptomatic relief and help in the healing process.   
Medical Management in Paradoxical Worsening 
Being an inflammatory reaction, steroids has been used as a treatment option in patients 
with paradoxical worsening. Use of steroids is further supported by its use in patients 
with tuberculous meningitis (depending on Medical Research Council Stage) to prevent 
inflammatory complication post initiation of antitubercular therapy(52). Effectiveness of 
steroids is not well established with variable outcome in literature from rapid clinical 
improvement to persistence or worsening(53–56).  Use of corticosteroid will help in 
reducing the edema around the enlarged nodes and can decrease the symptoms due to the 
mass effect of the enlarged nodes.  
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Figure 4: Mechanism of action of corticosteroids in tuberculosis (Adapted from Novel 
Adjunctive Therapies for the Treatment of Tuberculosis 
A.A. Ordonez,1,2,3,§ M. Maiga,2,4,§ S. Gupta,2,4 E.A. Weinstein,1,2,4 W.R. 
Bishai,2,4 and S.K. Jain1,2,3,*)(57) 
 
In a retrospective study done at Chung Ang Hospital and Yong sang hospital,139 patients 
with pleural tuberculosis were reviewed, of which 32(23%) developed paradoxical 
worsening. Amongst these 32 patients, 18 patients needed additional treatment. Seven 
patients were initiated on steroids at 0.5 mg/kg/day showed improvement in symptoms 
within a median duration of 14 days. Patients who received steroids seems to have 
responded quicker than the non-steroid recipients(23). In a retrospective chart review 
done in Tunisia, amongst the 67 patients who had paradoxical worsening, only 2 received 
steroids, full dose antitubercular therapy was reinitiated on 7 (10.4%) patients and 
surgical excision was done in 48 (71.6%) patients. Another descriptive retrospective 
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study done in Tunisia with 181 patients with Tuberculous Lymphadenitis, 18 patients 
developed paradoxical worsening. All of them needed steroids with 15 of them showing 
improvement and 3 having persistent lymph nodes(11). 
Table 6: Treatment options described in literature 
 
Study with details Treatment used Steroid dosage and other 
remarks 
Hawkeye et al(12) 
109 patients with Lymph 
Node Tuberculosis 
Paradoxical Reaction – 25 
patients (23%) 
• Prednisone only – 
10 patients (37%) 
• Aspiration only – 7 
patients (26%) 
• Both – 4 patients 
(15%) 
• Neither – 6 patients 
(22%) 
 
• Mean dose: 60 
mg/day 
• Range: 20 – 90 
mg/day 
• Duration: 52.5 
days(mean); (Range 
14 – 169 days) 
 
Jung et al(23) 
139 patients with Pleural 
Tuberculosis 
Paradoxical reaction- 
• No additional 
treatment (14 
Patients) 
• Steroids – 7 patients 
• Prednisone – 0.5 
mg/kg 
• Improvement within 
a median duration of 
14 days 
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32(23%) • Simple drainage – 7 
patients 
• Thoracotomy – 4 
patients 
• Rapid recovery in 
the steroid arm 
Chahed et al(9) 
Retrospective review of 
501 patients with lymph 
node tuberculosis 
Paradoxical reaction – 67 
patients (13.4%) 
• Steroids – 2 (3%) 
• Restarting ATT – 7 
(10.4%) 
• Surgical excision – 
48(71.6%)  
• Ciprofloxacin – 
13(19.4%) 
• Addition of 
Ethambutol – 9 
(13.4%)  
• Continuation of 
classic treatment – 
2(3%)  
• No details about 
steroid dosage 
available 
 
Smaoui et al(11) 
181 patients with TB 
Lymphadenitis 
• All 18 patients 
received adjunctive 
steroids 
• 15 patients showed 
improvement 
• 3 had persistent 
lymphadenopathy 
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Paradoxical reaction – 18 
patients (12%) 
Geri et al(7) 
76 Patients with 
tuberculosis with atleast 1 
extrapulmonary 
involvement 
Paradoxical reaction – 19 
(25%)  
• Surgical treatment – 
11 patients 
• Steroids – 9 patients 
• Extension of ATT 
duration – 4 patients  
• No specific 
treatment – 5 
patients 
• 0.5 mg/kg 
• Median duration of 
extension of ATT -  
3 months 
Cheng et al(21) 
Review of 122 episodes of 
paradoxical worsening 
across literature 
• Steroids – 48 
(39.3%) 
• Surgical 
intervention – 74 
(60.7%) 
• Change in 
Antitubercular 
Regime – 19(15.6%) 
• Conservative 
management – 17 
(13.9%)  
• 95 episodes resolved 
with complete 
recovery 
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In a retrospective study done in Paris between 2000 and 2010, consisting of 76 patients 
with tuberculosis with at least 1 extrapulmonary involvement, paradoxical worsening 
occurred in 19 patients, of which 9 patients received steroids, 4 patients were just 
continued antitubercular therapy for an extended period, 11 patients needed surgical 
drainage and 5 patients did not receive additional treatment. Another interesting finding 
in this study was while treatment for paradoxical worsening was going on paradoxical 
worsening recurred in 4 patients at least once. Two of them needed surgical treatment and 
3 needed oral steroids(7). Chen et al, reviewed 122 episodes of paradoxical worsening, of 
which about two-thirds patients needed surgical treatment, close to 40% needed steroids 
and more than two-thirds recovered with no residual disease(21).  
Long term use of steroids would be associated with steroid induced diabetes mellitus, 
hypertension, and weight gain. TNF-α plays a major role in the granuloma formation and 
in the inflammatory reaction in patients with paradoxical worsening to the mycobacterial 
antigens, as explained in the pathogenesis section of this dissertation. TNF-α blockade, 
seems to be other options in patients with recalcitrant paradoxical worsening. Options of 
TNF-α blockers include, anti TNF blockers like infliximab, adalimumab, etanercept; 
other TNF blockers like Thalidomide which seems to reduce leukocytosis, brain 
morphology and the symptoms in rabbit models and Pentoxiphylline(57). There are case 
reports, showing the beneficial effects of use of Infliximab in curbing the inflammatory 
response in neurotuberculosis(58). Thus, this could also be a therapeutic option, even 
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though there are not many studies to substantiate the same, which is important, especially 
with the known fact that, TNF-α blockers are known to reactivate latent tuberculosis.  
Other options described are Phosphodiesterase inhibitors, which increase intracellular 
cyclic AMP levels which in turn decrease the TNF-α levels. Animal models of 
tuberculosis have shown beneficial effects with the adjunctive use of PDE-I which 
include Theophylline, Cilostazol, Sildenafil, Tadalafil and Rofilumast(57,59,60). 
Thus, treatment of Paradoxical worsening can be summarized as: 
1. Medical Management 
a. Conservative Management – wait and watch 
b. Restarting/continuing Quadruple Antitubercular Therapy 
c. Corticosteroids – 0.5 mg/kg – 1 mg/kg, short course 
d. Newer options: (Not proven) 
i. TNF-α blockers – Pentoxiphylline, Thalidomide 
ii. Specific TNF-α blockers – Infliximab, Etanercept, Adalimumab 
iii. Phosphodiesterase inhibitors – Theophyline, Cilostazol, Sildenafil, 
Tadalafil and Rofilumast 
2. Surgical Management 
a. Incision and drainage of abscess 
b. Lymph node excision 
c. Lymph node excision with debridement 
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Figure 5: Treatment algorithm proposed, adapted from chahed et al(9) 
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MATERIALS &METHODS 
Setting 
This study was carried out in Christian Medical College (CMC), Vellore, which is 
a 2700-bedded tertiary care teaching hospital in South India. The hospital serves the 
population of Tamil Nadu and the neighboring state of Andhra Pradesh, besides being a 
referral center for patients from other parts of the country and the Indian subcontinent. 
Patients were recruited from May 2016 through June 2017 and were followed up 
till 6 months after recruitment. Patients who were recruited in the month of May 2017 
and June 2017 were followed up till the completion of intensive phase.  
Study Design 
This was a prospective cohort study in which patients with tuberculous 
lymphadenitis(TBLN) initiated on antitubercular therapy(ATT) were followed up to look 
for development of paradoxical worsening and identify possible risk factors for its 
development 
Participants 
A consecutive sampling strategy was employed for this study, wherein all patients above 
the age of 15 years, who presented with tuberculous lymphadenitis to outpatient and 
inpatient departments of Infectious Disease, Medicine and Surgery, at CMC Vellore, 
were enrolled into this study.  
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Inclusion criteria: 
Patients > 15 years with peripheral Tuberculous lymphadenitis: 
a. who were planned for initiation of antitubercular therapy or  
b. Who were already on antitubercular therapy for less than 30 days and presented to 
us for reconfirmation of diagnosis 
Exclusion criteria: 
a. Isolated Mediastinal or abdominal lymph nodal involvement with tuberculosis 
b. Human Immunodeficiency Virus(HIV) infection 
c. Multidrug resistant tuberculosis(MDR) or Extensively drug resistant 
tuberculosis(XDR) as identified on tissue sample by molecular or culture 
techniques 
d. Patients with connective tissue disorder or malignancies or immunodeficiency 
e. Patients who have been on steroids and immunosuppressants 
 
Study Procedure: 
 
All patients with confirmed or probable tuberculous lymphadenitis who were to be 
initiated on antitubercular therapy presenting to Outpatient and Inpatient Department of 
Infectious Disease, General Surgery and General Medicine were approached for 
participation in the study. A written informed consent was obtained from those eligible 
and willing to participate. In case of patients less than 18 years, consent was taken from 
the guardian after explaining the nature of the study to the patient.  
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Case definitions: 
Confirmed Tuberculous Lymphadenitis(TBLN): Patients were considered as confirmed 
tuberculous Lymphadenitis when the patient had characteristic clinical findings, 
histopathological findings of tuberculous lymphadenitis with PCR/culture positivity for 
Mycobacterium tuberculosis in the tissue sample.  
Probable Tuberculous Lymphadenitis: Patients were considered as probable tuberculous 
Lymphadenitis when clinical and histopathological findings were characteristic of 
tuberculous lymphadenitis with negative microbiology and positive response to therapy.  
Paradoxical Reaction/ Worsening (PR): Patients with tuberculous lymphadenitis was 
diagnosed to have Paradoxical worsening if the patient fulfilled the following diagnostic 
criteria which was adapted from previous studies on paradoxical worsening: 
A. Initial improvement after initiation of antitubercular therapy 
B. Worsening of symptoms: 
a. At the primary site: increase in the size of the lymph node, development of 
tenderness, fluctuation and sinus formation 
b. Development of new nodes with or without signs of inflammation at a site 
anatomically distant from the previous site 
C. Absence of MDR tuberculosis, poor compliance, impaired digestive absorption 
D. Absence of any other explanation for the deterioration 
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Being a referral centre and from our experience we had found that there was this distinct 
group of patients who were on antitubercular therapy from elsewhere and presented to 
our centre with paradoxical worsening assuming drug resistance or clinical failure. If we 
were to exclude these patients we were likely to miss valuable information characterizing 
this distinct cohort of patients. Hence, we designed the study to incorporate these 
patients, thus having two arms of recruitment.  
Patient recruitment and assessment: 
 
 
Incident cohort:The first cohort included patients diagnosed with TB lymphadenitis for 
the first time at our centre. This also included patients who were diagnosed elsewhere but 
were on ATT for less than 30 days. These patients would not be having paradoxical 
reaction at presentation.  
Paradoxical Reaction/Worsening (PR) cohort:The second cohort would include all 
patients who presented with paradoxical worsening at first presentation to our centre. 
This design incorporating two arms was done to facilitate obtaining a possible incidence 
of development of paradoxical worsening as well as define this PR group better in view 
of the low incidence in previous literature.  
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BASELINE ASSESSMENT FOR THE INCIDENT COHORT: 
At baseline, lymph node groups, which were involved were identified by clinical 
examination. Both clinical and laboratory parameters were assessed for these patients at 
baseline which were as follows: 
Clinical parameters 
a. Size of the lymph node 
b. Site of lymph node 
c. Number of lymph nodes 
d. Presence of local tenderness 
e. Presence of fluctuation 
f. Presence of discharge 
 
Assessment of the size of lymph node 
To avoid interobserver variation in the measurement of lymph nodal size, a standardized 
technique was used for the measurement of lymph nodal size between patients and also 
for the same patient during the course of treatment. Following steps were followed: 
1. Vernier calliper was used for all measurements of lymph node 
2. The lymph node in question was held with two fingers 
3. The outline of the lymph node was drawn 
4. Largest diameter was measured 
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5. Diameter of a line which is perpendicular to the largest diameter was then 
measured 
6. These measurements were done 3 times and an average was taken 
7. Photograph of the lymph node were taken and stored for future purpose 
These steps were followed at each measurement subsequently at follow-up. 
Laboratory parameters: 
Laboratory parameters assessed at baseline included: 
a. Hemoglobin 
b. Erythrocyte Sedimentation Rate(ESR) 
c. C- Reactive Protein 
d. Total WBC count, Differential Count, Absolute Lymphocyte count(calculated) 
e. CD4 count.  
Details regarding patient demographics, clinical findings – lymph node size, 
characteristics and above test results were entered in a data abstraction sheet designed for 
this study. Subsequent patient evaluation and management was entirely at the discretion 
of the treating physician.  
FOLLOW-UP OF THE INCIDENT COHORT: 
The study participants were followed-up at the end of intensive phase (2 months) and 
then at end of treatment which varied from 6-9 months. At each follow-up visit, 
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following clinical and laboratory parameters were assessed, to check if they had 
developed a PR: 
Clinical Parameters 
a. At the primary site of involvement: 
a. Size of lymph node: any increase or decrease in size of lymph node 
b. Number of the lymph node: any increase in the number of lymph node 
c. Presence of local tenderness (newly detected) 
d. Presence of fluctuation (newly detected) 
e. Presence of discharge (newly detected) 
b. At other sites: 
a. Any new nodes which were not present in the previous visit 
b. Assessment for signs of inflammation 
Laboratory parameters 
Following laboratory parameters were assessed at each follow-up visit: 
a. Hemoglobin 
b. ESR 
c. CRP 
d. Absolute Lymphocyte count (ALC) 
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PR COHORT AT FIRST VISIT 
These patients were diagnosed to have Paradoxical worsening based on history and 
clinical presentation as reported by patients and fulfilling the criteria as per our definition. 
Similar clinical and laboratory parameters were assessed for this group as well.  
At the time of diagnosis of paradoxical reaction in the incident cohort and the PR cohort, 
apart from the aforementioned parameters, poor drug compliance and drug resistance 
were also assessed. We performed a pill count, followed up previous cultures to rule out 
resistance (Incident cohort) and if there was a doubt of the same, repeat biopsy was 
advised to the patient for confirmation of the diagnosis and performed if the patient 
consented for the same. In case of lymph node abscess if surgical 
aspiration/debridement/drainage was planned for therapeutic purposes, confirmation was 
done based on pus mycobacterial PCR and/or culture positivity.  
Outcomes assessed 
PRIMARY OUTCOME: 
To determine the proportion of patients diagnosed as tuberculous lymphadenitis developing 
Paradoxical worsening. 
SECONDARY OUTCOME: 
To elaborate the clinical profile of patients developing Paradoxical worsening 
To identify baseline clinical and laboratory parameters, which could predict the occurrence of 
paradoxical worsening in this cohort 
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Sample Size 
We utilized the observational study done by Dr Vincent Cheng to calculate the sample size for 
the study. In his observational study, the incidence of paradoxical reaction ranges from 10-15%. 
Implementing these values, 
 
    N = 4pq/d2 
                                 p = 0.10, q = 1-0.10= 0.90 
                                 d = 0.05 
                                 N = 138 
Statistical Analysis: 
 
Data entry was done using EPIINFO Software. Frequencies in the 2 groups – Paradoxical 
Reaction versus non-Paradoxical Reaction were estimated and univariate analysis was 
done using chi-square test for dichotomous variables and a students’ T test for continuous 
variables. 
 
Institutional review board and ethics committee clearance: 
 
The study design and methods were approved by the institutional review board (blue) 
and ethics committee of Christian Medical College, Vellore (IRB Min. No. 10021 dated 
04.04.2016). A copy of the IRB approval statement can be found in Annexure 1. 
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Funding of the study: 
This study was funded by fluid research grant number 22Y909 of Christian Medical 
College, Vellore. 
 
As per the study design, we recruited consecutive patients with tuberculous 
lymphadenitis presenting to Infectious Diseases, General Medicine and surgery outpatient 
and inpatient departments.  Patients who were later found to have an alternative 
diagnosis, Multidrug resistant and Extensively Drug Resistant Tuberculosis were 
excluded from the study 
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Study Flow Diagram: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6: Study flow diagram 
 
STEP 1: CLEAN MINOR/FNAC ROOM/MED OPD-
WARD/SURG OPD-WARD 
Patients with fever, weight loss and peripheral lymph nodal 
enlargement 
Phone number obtained 
STEP 2: RECRUITMENT OF PATIENTS 
Biopsy/FNAC results followed up 
All patients with probable and confirmed tuberculous 
lymphadenitis contacted 
Take consent and fill the baseline details 
PR COHORT 
Included:  
 Patients who presented to 
CMC with features suggestive of 
paradoxical reaction as mentioned in 
the case definition. Drug non-
compliance, poor drug absorption and 
,drug resistance were ruled out.  
INCIDENT COHORT 
Included:  
1. Patients who presented with a clinical 
picture of TB Lymphadenitis and were 
not on ATT 
2. Patients who had been diagnosed 
elsewhere and started on antitubercular 
therapy for < 30 days 
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STEP 3: BASELINE CLINICAL AND LABORATORY ASSESSMENT  
Clinical assessment: Lymph node size, site, number, fluctuation, tenderness or sinus  
ESR/CRP 
ALC/CD4 
Weight based ATT initiation by the treating physician 
STEP 4: ASSESSMENT AT PR(EVENT), END OF INTENSIVE PHASE AND 
CONTINUATION PHASE 
Clinical assessment: Lymph nodal size, fluctuation, tenderness and sinus  
                                                                ESR/CRP 
ALC 
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RESULTS 
This prospective cohort study was done from May 2016 through June 2017. During this 
period 80 patients were recruited. Four patients were excluded, as one patient refused to 
provide consent, one patient had an alternative diagnosis and the other 2 had multidrug 
resistant tuberculosis. Thus, seventy-six (N= 76) patients were included in the final 
analysis (Figure 7). 
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CONSENTED TO PARTICIPATE 
N = 79 
 
PATIENT INCLUDED FOR ANALYSIS 
N = 76 
 
REFUSED CONSENT 
N= 1 
3 PATIENTS 
EXCLUDED 
1 – ALTERNATIVE 
DIAGNOSIS 
2- MDR Tuberculosis 
 
MET ELIGIBILITY CRITERIA 
N = 80 
 
PATIENTS IN THE PROSPECTIVE COHORT 
N= 70 
PATIENTS WHO PRESENTED WITH 
PARADOXICAL WORSENING 
N = 6 
Figure (7) STROBE Diagram 
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INCIDENT COHORT 
Baseline characteristics of the incident cohort (N = 70) 
 
There were 70 patients who belonged in the incident cohort. Of the seventy patients in 25 
were men and 45 were women. Mean age of the cohort was 33.33 (IQR: 25 – 42.25) 
years. Close to half the patients belonged to Tamil Nadu, one-third were from West 
Bengal and the remainder from the rest of the country. This distribution of patients from 
different parts of the country can be explained as we are a tertiary referral centre 
providing services to the whole country. About 10% patients were already on 
antitubercular therapy at the time of recruitment. 72% patients had exclusive peripheral 
lymph nodal involvement whereas 28% of these patients had additional organ  system 
involvement. Other baseline characteristics are described in the table 8.  
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Table 8: Baseline characteristics of the incident cohort (N = 70) 
 
Sex Male – 25 
Female – 45 
Mean Age 33.33 (IQR: 25 – 42.25) 
Patients previously treated with ATT 7 (10%) 
Extralymph nodal involvement 19(27.1%) 
Patient Residence 
• Tamil Nadu 
• West Bengal 
• Kerala 
• Karnataka 
• Others 
 
• 34 (48.6%) 
• 21 (30%) 
• 1 (1.4%) 
• 1 (1.4%) 
• 13 (18.6%) 
Patients who were on ATT prior to 
presentation 
7 (10%) 
 
 
Clinical, Laboratory and Microbiological characteristics of these patients are summarized 
in table 9. Only 8 patients (11.4%) had a positive AFB smear from the lymph node 
biopsy. Xpert TB PCR was positive in 33 patients (47.14%) with none of them having 
Rifampicin resistance. There was eventual culture growth in 34 patients (48.57%). 
Amongst the patients in whom sensitivity results were available, 23 were pansensitive. 
However, there were 4 patients who had drug resistance to at least 1 drug, none of them 
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had multidrug resistant or extensively drug resistant Tuberculosis. Lymph node 
histopathology showed well-formed granulomas in 53 patients (75.71%) and necrosis in 
60 patients (85.71%). Most commonly involved lymph nodes were cervical nodes. In 
most instances, there was only single node involvement. At presentation, we found 8 
patients had tenderness and fluctuation, 1 had discharge and 5 had sinuses.  
Table 9: Clinical, Laboratory, Microbiological and Histopathological characteristics of 
Patients in the Incident Cohort 
 
Clinical characteristics 
Site of Lymphadenopathy 
• Right Cervical 
• Left Cervical 
• Right Axillary 
• Left Axillary 
• Inguinal 
 
• 48 
• 35 
• 4 
• 1 
• None 
Average Lymph node size 3.594 X 2.807 cm 
Signs of inflammation at presentation 
Tenderness 
Fluctuation 
Discharge 
Sinus 
14/70 
– 8 
– 8 
– 1  
– 5 
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Laboratory Parameters 
Hemoglobin (median) 12.22 (IQR: 11.03 – 12.20) 
Absolute Lymphocyte Count (median) 1587 (IQR: 1216 – 2231) 
ESR (median) 36 (IQR: 16 -50) 
CRP (median)  11.9 (IQR: 3.35 – 30.9) 
CD4 (median) 662 (IQR: 476 – 822) 
Microbiological Parameters 
AFB smear positive 8 (11.4%) 
Culture Growth – Present 34(48.6%) 
Xpert TB PCR – Positive 33 (47.1%) 
Pansensitive organism 23 
Resistance to one drug(Isoniazid, 
Streptomycin) 
4 
Histopathological characteristics 
Well-formed granulomas 53 (75.7%) 
Presence of necrosis 60 (85.7%) 
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Histograms below show the distribution of Hemoglobin, Absolute Lymphocyte count, 
ESR and CD4 counts among the 70 patients in the prospective arm.  
 
Figure 8: Distribution of Hemoglobin in the incident cohort 
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Figure 9: Distribution of Baseline Absolute Lymphocyte count in the incident cohort 
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Figure 10: Distribution of Baseline ESR in the incident cohort 
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Figure 11: Distribution of baseline CRP in the incident cohort 
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Figure 12: Distribution of baseline CD4 in the incident cohort
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INCIDENT COHORT – PATIENTS WITH PR VERSUS THOSE WITHOUT PR 
 
Four patients in the incident cohort developed paradoxical worsening. Clinical, 
laboratory, microbiological and histopathological features of these 4 patients were 
compared against the rest of the cohort.   
 
Figure 12: Gender distribution 
 
At baseline, mean size of the lymph nodes were almost the same in the two groups. In 
terms of the signs of inflammation, we found that of the 4 patients, 1 (25%) had signs of 
inflammation at the baseline whereas of the 66 patients, 5 (7.6%) had signs of 
inflammation. In terms of laboratory parameters, median values of baseline hemoglobin, 
Absolute Lymphocyte count, ESR and CRP were similar in both the groups. Of the 4 
patients who developed paradoxical worsening, we only had baseline CD4 count for one 
patient which was 719. Median CD4 count for the Non-PR arm was 657.  
23
2
43
2
N O  P A R A D O X I C A L  W O R S E N I N G D E V E L O P E D  P R
GENDER DISTRIBUTION IN TWO GROUPS
Male Female
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A comparison of the microbiological and histopathological characteristics of the two 
groups in the INCIDENT COHORT are summarized in table 10.  
Table 10: INCIDENT COHORT – Patients who developed PR versus those who did not 
(BASELINE DATA) 
Comparison of the baseline Clinical, Laboratory, Microbiological and Histopathological 
characteristics 
 
 PR Arm 
N = 4 
Non-PR arm 
N = 66 
Baseline Clinical Characteristics 
Mean Age 31.75 (IQR: 23.5 – 
38.75) 
33.42 (IQR: 25 – 
43) 
Sex distribution (M/F) 2/2 23/43 
Average size 2.8 X 1.97 cm 2.49 X 1.97 cm 
Signs of inflammation 
(tenderness, fluctuation and sinus – any 
one of them) 
1 5 
Baseline Laboratory Characteristics 
Hemoglobin (median) 12.25 
(IQR: 10.15 – 
13.075) 
12.2 
(IQR: 11.025 – 
13.0) 
Absolute Lymphocyte Count (median) 1460 1628 
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(Range: 664 – 
1587) * 
(IQR: 1229 – 2232) 
ESR (median) 38.5 
(IQR: 29.75 – 
47.25)  
32 
(IQR: 15 – 50) 
CRP(median) 16 
(Range: 11.9 – 
46.7) * 
11.1 
(IQR: 3.21 – 29.9) 
CD4 (median) 719*** 657 
(IQR: 467 – 830) 
 
Baseline Microbiological and Histopathological Characteristics 
AFB smear positive 1(25%) 7 (11.1%) 
Xpert TB PCR 4(100%) 29 (49.2%) 
Culture growth present 3(75%) 31 (50%) 
Sensitivity  
1. Pansensitive 
2. Monoresistance 
 
3 
0 
 
20 
4 
Baseline Biopsy 
1. Well-formed Granulomas 
2. Necrosis 
 
2(50%) 
2(50%) 
 
51(77.3%) 
58 (87.7%) 
68 
 
 
*1 missing 
**2 missing 
***3 missing 
There was no significant change in the median absolute lymphocyte count at baseline, at 
the end of intensive phase, at the time of PR and at the end of continuation phase between 
the two groups.  
Figure 13: Median ALC values across the duration of treatment 
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There was no significant change in the median values of ESR when measured at the end 
of intensive phase, at the time of PR and at the end of continuation phase between the two 
groups.  
 
Figure 14: Median ESR across the duration of treatment 
 
There was no significant change in the median values of CRP when measured at the end 
of intensive phase, at the time of PR and at the end of continuation phase between the two 
groups.  
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Figure 15: Median CRP across the duration of treatment 
 
Amongst the patients in the PR group, re-biopsy was done in 2 of these patients, Xpert 
TB PCR was positive in both, AFB smear and culture was positive in 1 patient and the 
mycobacterium was pansensitive in that case. Histopathology of both the biopsies 
showed well-formed granulomas and necrosis. 
 
 
16
4.9 4.8
11.1
3.19
4.87
0
2
4
6
8
10
12
14
16
18
Baseline Event/ 2 months End of treatment
C
R
P
 V
al
u
es
Months
Median CRP Value during the course of treatment
PR Non PR
71 
 
Table no 11: Parameters at the time of paradoxical worsening in the incident cohort 
Clinical, Laboratory, Microbiological and Histopathological characteristics at the 
time of Paradoxical Worsening in the Incident Cohort 
Average size 4.83(Range 3.5 – 7.0) cm 
Hemoglobin (median) 12.1 (Range: 7.2 – 14.3) ** 
Absolute Lymphocyte Count (median) 1920 (Range: 206 - 1984) * 
ESR (median) 16 (IQR: 6.25 – 48.25) & 
CRP (median)  4.9 (Range: 3.02 – 7.23) * 
CD4(median) 384 (Range: 78 – 691) ** 
Rebiopsy Status  Done – 2 
Not Done – 2 
AFB smear Status in the repeat biopsy 
sample 
Positive – 1 
Negative – 1 
Xpert TB PCR Status in the repeat biopsy 
sample 
Positive – 2 
Negative -0 
Culture growth status from the repeat 
biopsy sample 
Present – 1 (Pansensitive) 
Absent – 1  
Histopathology in repeat biopsy sample 
a. Well-formed granulomas 
b. Presence of necrosis 
 
 
a. 2 
b. 2 
*1 missing 
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**2 missing 
***3 missing 
FACTORS ASSOCIATED WITH PARADOXICAL WORSENING 
 
Table 12: Univariate analysis of possible risk predictors at baseline 
Variable PR  
N = 4 
(Median) 
Non – PR 
N = 66 
(Median) 
Odds Ratio 95% CI P value 
Clinical Variables at baseline 
Age < 40  4  46 0.920 0.848 – 0.998 0.319 
Sex (M/F) 2/2 23/43 1.87 0.27 – 14.154 0.613 
Size >2 cm at 
baseline 
1 7 0.57 0.05 – 6.27 0.530 
Any signs of 
inflammation 
(discharge, 
tenderness, 
fluctuation) 
1 5 4.067 0.35 – 46.65 0.30 
Laboratory Variables at baseline 
Baseline 
Hemoglobin 
12.25 12.2   0.874 
Baseline ALC 1460 1628   0.294 
73 
 
Baseline ESR 38.5 32   0.683 
Baseline CRP 16 11.1   0.325 
Baseline CD4 719 657   0.906 
Microbiological Variables at baseline 
AFB smear 
positivity at 
baseline 
1 7 2.67 0.24 – 29.26 0.406 
Xpert TB 
Positivity at 
Baseline 
4 29 ∞  0.115 
Culture Positivity 
at baseline 
3 31 3 0.29 – 30.44 0.614 
Histopathological Variables at baseline 
Well-formed 
granulomas 
2 51 0.216 0.027 – 1.701 0.171 
Necrosis 2  58 0.069 0.008 – 0.626 0.039 
 
Apart from presence of necrosis at baseline, no other baseline characteristics had any 
significant association with the occurrence of PR. Event numbers were not big enough for 
us to draw a reasonable conclusion. 
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PR COHORT 
Baseline characteristics 
 
During the process of recruitment, we identified 6 patients who satisfied the diagnostic 
criteria for PR (as mentioned in the case definition section) at presentation itself. Even 
though we did not have baseline data for these patients, we also followed up these 
patients to better understand the natural history of these patients especially because we 
had such a low incidence of paradoxical worsening in our incident cohort. Half of these 
patients had signs of inflammation and the rest presented with increase in the size of the 
node from before (based on patient history).  Average size of the nodes at presentation 
was 3 X 3.3 cm.  Baseline Hemoglobin, ALC, ESR, CRP and CD4 count were similar to 
the patients in the incident cohort. 
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Table 13: Baseline Characteristics of Patients presenting with Paradoxical Worsening 
 
Hemoglobin (median) 11.35 (IQR: 10.68 – 13.25) 
Absolute Lymphocyte Count (median) 1827(IQR: 1398.75 – 2336.25) 
ESR (median) 31 (IQR: 18.75 – 59.25) 
CRP (median)  20.8 (IQR: 3.16 – 36.95) 
CD4 (median) 676 (IQR: 359 – 1230.50) 
Average size 3 X 3.3 cm 
AFB smear negativity 6(100%) 
Culture Growth – Absent 6(100%) 
Xpert TB PCR – Positive 3(50%) 
Well-formed granulomas 5(83.3%) 
Presence necrosis 4(66.7%) 
 
The above table reiterates the fact that, paradoxical worsening is purely an inflammatory 
reaction, with the absence of Culture growth or AFB Smear positivity. Xpert TB PCR 
being a PCR, can detect even dead nonviable bacilli. Most of these patients had well-
formed granulomas with necrosis. 
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Treatment Characteristics of the Entire Cohort (INCIDENT + PR COHORT) 
 
We found that patients in this study received varying duration of antitubercular therapy (6 
– 22 months) due to continued and worsening clinical symptoms. Mean duration of ATT 
consumption was 10 months with the median and mode being 9 months with an 
interquartile range from 8.25 to 10.75 months. Of the 76 patients, 34 patients completed 
antitubercular therapy while on follow-up in the study while the remaining were still 
completing their treatment course. 10 patients were lost to follow-up.  
Mean time to Paradoxical worsening was 3.25 months (2 – 5 months). Amongst the 10 
patients who had paradoxical worsening (6 patients in PR arm and 4 patients in the 
prospective arm), 8 patients had progression (worsening of the pre-existing lymph node) 
and 2 patients had dissemination (development of new nodes elsewhere).  
 
 
77 
 
 
Figure 16: Patients with Paradoxical worsening in our cohort 
 
Four patients underwent surgical debridement of which 3 underwent unilateral limited 
neck dissection and 1 underwent bilateral neck dissection with excision of sinuses. One 
patient received steroid, 3 patients received pentoxiphylline and 3 were managed 
conservatively with continuation of antitubercular therapy. 
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Table 14: TREATMENT CHARACTERISTICS OF PATIENTS WITH PARADOXICAL WORSENING 
(N = 10) 
 
Total number of patients 76 
Patients in the prospective Arm 70 
PR in the incident cohort  6 
PR Cohort  4 
Mean size of node at the time of event 4.375 X 3 cm 
Mean Time to Paradoxical Worsening 3.25 (2 – 5) months 
Type of PR 
A. Progression 
B. Dissemination 
 
a) 8 
b) 2 
Management 
A. Conservative Management 
B. Surgical Management 
C. Steroid 
D. Pentoxiphylline 
 
a) 3 
b) 4 
c) 1 
d) 3 
Surgical Management 
 
Unilateral Limited Neck Dissection (3) 
Bilateral Limited Neck Dissection with 
excision of Tuberculous Sinuses (1) 
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DISCUSSION 
 
Paradoxical worsening is an exuberant inflammatory reaction, in a patient with 
tuberculosis on antitubercular therapy, characterized by initial improvement followed by 
development of clinical or radiological worsening in the absence of evidence of drug 
resistance or presence of another diagnosis(5). Paradoxical worsening has varied 
manifestation depending upon the site of involvement and the extent of involvement. It 
could be clinical worsening with development of an abscess or discharging sinus at the 
previously involved site, or it can involve completely new site or organ system for 
example development of pleural effusion, intrabdominal node or a mere lymph nodal 
enlargement elsewhere. Even though it’s a well described entity in literature, 
understanding of this unique phenomenon is limited amongst the scientific community. 
Most of the studies on paradoxical worsening have come from western populations. It can 
be said that paradoxical worsening is underdiagnosed in our population, a population in 
which 2.2 million people develop Tuberculosis every year. Importance of diagnosing this 
phenomenon is mainly because most of these patients are diagnosed as drug resistant 
tuberculosis and are initiated on second line and third line antitubercular therapy. Thus, it 
becomes important to identify key features which will help a clinician recognize this 
entity and to identify baseline risk factors which could predict its occurrence.  
This study involved a prospectively enrolled cohort of 76 patients with tuberculous 
lymphadenitis who presented to a tertiary care center in South India. Six of these patients 
presented with paradoxical worsening at their first visit itself. Four patients developed 
80 
 
paradoxical worsening in the incidence arm making an incidence of 5.71 % in our 
incident cohort. This incidence seems to be in keeping with the incidence described in 
literature for paradoxical worsening which ranges from 2.3 – 23% in literature (63).  
Among the 10 patients who had paradoxical worsening, mean time to paradoxical 
worsening was 3.25 months ranging from 2 months to 5 months. In literature the mean 
time to occurrence of paradoxical worsening is varied but ranges from as short as 14 days 
to as long as 280 days(8,9,7,21,24,36).   
Clinical manifestation of all our patients with paradoxical worsening was characterized 
by an increase in size of the lymph node, noticing new signs of inflammation (tenderness, 
fluctuation, sinus and discharge) in these nodes and development of nodes elsewhere. We 
found most of our patients had worsening at the primary site of tuberculosis rather than at 
a distant site. This description of paradoxical worsening is like what is described in 
literature.  
We found that all the patients who developed paradoxical worsening had a negative AFB 
smear result and culture result at the time of the event except for 1 patient (described 
later). This emphasizes that in these patients this worsening is due to exaggerated host 
response rather than persistence of bacilli or drug resistance or treatment failure. 
However, Xpert TB PCR was positive in half of these patients possibly due to detection 
of non-viable bacilli. Thus, a positive Xpert TB PCR to be positive in this clinical setting 
should not be misconstrued as clinical failure or drug resistance leading to a change in 
therapy. Histopathologically, we identified that at the time of paradoxical worsening, 
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most of these patients had well-formed granulomas (87.5%) with necrosis (75%) 
reiterating the hosts immune response at these sites.  
In literature, various risk predictors are described which we tried to look for in our 
analysis. We did not find any significant association with age, sex, lymph node size, signs 
of inflammation at baseline, associated extra-nodal disease, absolute lymphocyte count 
values at baseline, anemia at baseline, positive AFB smears and TB cultures at baseline. 
We found that presence of necrosis at baseline in the lymph node biopsy was the only 
variable associated with the occurrence of paradoxical worsening in the future. We must 
also consider, that the event occurred only in 4 patients amongst the 70 patients. Due to 
the small number of events, we may not have been able to identify any significant 
association which is a major limitation of our study.  
An interesting finding in one of our patients, was that even after being diagnosed with 
paradoxical worsening on treatment, this patient developed 3 distinct new successive 
episodes of paradoxical worsening despite undergoing surgical management and being on 
appropriate antitubercular therapy. She developed repeated episodes of what events 
which could be termed as paradoxical worsening. However, repeated cultures grew 
pansensitive mycobacterium tuberculosis and she was never treated as Multidrug 
Resistant Tuberculosis and did receive a total of 18 months of antitubercular therapy. 
This was a rather interesting phenomenon as we felt there was a slow clearance of the 
tuberculosis in this case. This rather rare occurrence is described in literature by Geri et 
al, who identified 19 patients with paradoxical worsening, amongst whom 4 developed a 
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repeat event of paradoxical worsening. Most of the repeat events were at the same site as 
the first Paradoxical worsening and occurred within a mean duration of 2 months from 
the first episode and half of them required debridement/excision(7). 
In our patients who developed paradoxical worsening, 4 out of 10 needed surgical 
debridement, which included Unilateral Limited Neck Dissection and Bilateral Limited 
Neck Dissection with excision of Tuberculous Sinuses. We also found that when we 
intervened surgically response was better and they did not seem to need adjunctive 
steroids or anti TNFα therapy. We had only one patient who received steroids. 
Pentoxiphylline was the only TNFα blocker which was used in our patients. We did not 
use monoclonal antibodies directed against TNFα or Thalidomide in any of our patients. 
Thus, surgical management seemed to eliminate the local reflex arc more effectively 
reducing the need for alternative therapy, reducing symptoms of the patients and the 
duration of anti-tubercular therapy.  
CD4 count was used in our study as a surrogate marker for cell mediated immunity and 
for the ensuing inflammation. In patients with tuberculosis, CD4 counts having been 
found to be subnormal, as described in a study done in an Ethiopian population with HIV 
negative Pulmonary tuberculosis. This study showed that patients with lower CD4 count 
seemed to be more often sputum smear positive with significant wasting. With treatment, 
there was improvement in these parameters (64). Hence, we checked CD4 counts at 
baseline, however baseline CD4 count did not seem to predict the occurrence of 
paradoxical worsening. However at the time of paradoxical worsening, when we repeated 
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the CD4 count, we found that there may have been a decline in the CD4 count(61). Thus, 
paradoxical worsening may have an associated low CD4 count, although a definite 
association could not be established. The mechanism for this could be that exaggerated 
inflammatory reaction would results in increased sequestration of the cells to the sites of 
inflammation resulting in increased lowering in CD4 counts than that described in 
literature for HIV negative TB patients(62). In addition, there is increased homing of 
regulatory CD4 cells(CD4CD25+) cells in addition to T helper 1 and 2 cells to these sites 
especially in the setting of exaggerated inflammation(38). Literature suggests a drop in 
the CD4 counts of 100 cells/µL in patients with HIV negative Tuberculosis as compared 
to control(63). We suggest her that, CD4 counts do drop in a patient with tuberculosis, 
but it drops even further in patients who eventually develop paradoxical worsening. 
Thus, putting all the above findings together, we can infer that a patient presenting with 
worsening symptoms suggestive of paradoxical worsening can be differentiated from 
drug resistance, poor drug absorption or treatment failure with microbiological and 
histopathological clues of a negative AFB smear, negative tissue culture, low CD4 
count(<500) and well-formed granulomas with necrosis. This would need further 
validation for use in future research and clinical practice.  
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LIMITATIONS 
There were a few limitations in this study. Firstly, we did not achieve the sample 
size which we intended to, due to slow recruitment. However, to the best of our 
knowledge this would be one of the first studies which looked into the paradoxical 
worsening in a prospective manner, as most of the previous studies have been 
retrospective. Therefore, this study, despite its small sample size, provides a scaffolding 
for further research for this phenomenon, especially in identifying risk factors, predictors 
and treatment options. 
Secondly, the number of events which occurred in this cohort of patients were 
only 4, hence we were unable to come up with predictors of tuberculous lymphadenitis 
Thirdly, as we had to follow-up patients at 2 months and end of treatment (6 or 9 
months), we found it especially difficult to do the same as patients were from far off 
places, and usually most of our non-resident patients continue further care at their 
hometown. Thus, we lost quite a few valuable follow-up results.  We may have lost data 
on patients who developed subtle features of paradoxical worsening but did not seek 
medical attention as distance was an issue. Hence, we may be under estimating the 
incidence of paradoxical worsening in our study. 
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CONCLUSIONS 
In conclusion, this prospective study done on patients with tuberculous lymphadenitis, 
identified that the incidence of PR in our cohort was 5.71%. Patients with clinical 
features of paradoxical worsening had negative smear and culture suggesting an aberrant 
host response rather than drug resistance. This clinical entity needs to be publicized to 
prevent unnecessary, toxic and expensive empirical 2nd line Anti tubercular treatment. 
Our patients seem to respond better to surgical debridement rather than medical therapy 
possibly due to elimination of the local inflammatory reflex arc.  
Future research must be aimed at ensuring larger number of patient recruitment with 
emphasis on good follow-up by using the same model as we used in this study in terms of 
the measurement of lymph node, laboratory assessment at each visit. A robust study with 
larger numbers in India would help identify predictors for this phenomenon applicable to 
the Indian setting.  
In addition, studies must be done to elucidate the pathogenesis of this phenomenon, even 
though there are proposed theories, but none of them have been conclusively proven. We 
must perform studies to look at the cytokine response at baseline, end of intensive phase 
and end of treatment. We must understand that our understanding of tuberculosis 
pathogenesis is still at its nascent stage and more research is needed for the same. 
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Annexure 3 – Patient consent Sheet 
Format for Informed Consent Form for Subjects 
 
Informed Consent form to participate in a research study  
 
Study Title: To determine the clinical and laboratory risk predictors of paradoxical 
reaction in a cohort of patients with Tuberculous lymphadenitis during the course of 
treatment. 
                       
 
Study Number: ____________ 
 
Subject’s Initials: __________________ Subject’s Name: 
_________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
(Subject) 
 
(i)  I confirm that I have read and understood the information sheet dated 
____________ for the above study and have had the opportunity to ask 
questions. [  ] 
 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [  ] 
 
(iii)  I understand that the Sponsor of the clinical trial, others working on the 
Sponsor’s behalf (delete as appropriate), the Ethics Committee and the 
regulatory authorities will not need my permission to look at my health records 
both in respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the trial. I agree to this access. 
99 
 
However, I understand that my identity will not be revealed in any information 
released to third parties or published. [  ] 
 
(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). [  ] 
 
(v)  I agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______ 
 
 
 
 
 
Signatory’s Name: _________________________________         Signature:  
 
Or 
 
 
 
 
 
 
 
 
Representative: _________________ 
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Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
 
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
 
 
Signature or thumb impression of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name & Address of the Witness: ______________________________ 
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Annexure 4 – Data Abstraction Sheet 
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Annexure 5 – Data Sheet
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axilllt ingurt ingult afb culture xpert rifr sensit biopsy necrosis rcno rclsize rcbsize rctend rcfluct rcdis rcsin lcno lclsize lcbsize lctend lcfluct lcdis lcsin rano ralsize rabsize ratend
2 2 2 2 2.2 1.2 2 2 2 2
2 2 2 2 2 2 1 1 1 3 2 2 2 2 2
2 2 2 2 1 2 1 1 1 2 3 2.6 2 2 2 2
2 2 2 2 2 1 2 1 1 99 3 4 2 2 2 2
2 2 2 2 2 1 2 1 1 1 2 2 2 2 2 2 2 4 4 2
2 2 2 1 1 1 2 1 2 2 1 7 3.6 1 1 2 2
2 2 2 2 1 1 2 1 1 2 1 3 2 2 2 2 2
2 2 2 2 1 1 2 1 1 1 3 2.6 2 2 2 2 2 2 3.2 2.4 2 2 2 2
2 2 2 2 1 2 1 1 2 1 2.4 2.1 2 2 2 2
2 2 2 2 1 1 1 1 3 2.5 2 2 2 2
2 2 2 2 2 2 1 1 1 2 2 2 2 2 2
2 2 2 2 1 2 1 1 1 1 2 1 2 2 2 2
2 2 2 2 1 1 2 1 1 1 99 2 1 2 2 2 2
2 2 2 1 3 3 2 2 2 2 2 2 2 2 2 2 2
2 2 2 2 1 2 1 2 1 1 2 2 2 2 2 2
2 2 2 2 1 1 2 1 1 1 1 7.2 6.2 2 2 2 2
2 2 2 2 1 2 1 1 1 99 4 3 2 2 2 2
2 2 2 2 2 2 2 1 1 3 2.5 2 2 2 2
2 2 2 2 1 1 2 1 1 1 99 7 5 1 1 2 2
2 2 2 2 1 1 2 1 1 1 1 3 2.5 2 2 2 2
2 2 2 2 1 1 2 1 1 1 99 1 1 2 2 2 2 99 2 2 2 2 2 2
2 2 2 2 2 2 1 1 2 4.3 3.9 1 2 2 2
2 2 2 2 2 1 2 1 1 2 2.1 1 2 2 2 2
2 2 2 2 2 2 1 1 2 1 0.5 2 2 2 2
2 2 2 1 2 1 2 1 4.7 1.2 1 2 2 1
2 2 2 2 2 2 1 1 1 1 1 2 2 2 2 1 1 1 2 2 2 2
2 2 2 2 2 1 2 1 1 99 3 2 2 2 2 1
2 2 2 2 1 2 2 2 1 1 6.1 4.8 1 1 2 2
1 2 2 2 2 1 2 2 1 1 2 2 2 2 1 1 1 2
2 2 2 2 2 2 1 1 1 3 2 2 1 2 2
2 2 2 2 2 1 2 1 2 99 2 2 2 2
2 2 2 2 1 2 1 1 1 1 3.4 2.5 2 2 2 2 99 1 1 2 2 2 2
2 2 2 2 1 2 2 1 1 32 2.4 1.8 2 2 2 2
2 2 2 2 1 1 2 2 2 1 3.3 3 1 1 2 2
2 2 2 2 1 1 2 1 1 1 1 5 3 2 2 2 2
2 2 2 2 1 1 1 1 1 2.4 2.2 2 2 2 2
2 2 2 2 1 1 1 1 3 1 1 2 2 2 2
2 2 2 2 2 2 1 1 1 2.6 2.3 2 2 2 2
2 2 2 2 2 1 2 1 1 1 1.3 1 2 2 2 2 3 2.5 2.3 2 2 2 2
2 2 2 2 2 1 1 1 3 2.4 2 2 2 2
2 2 2 1 1 2 1 4.5 1.5 2 2 2 2 1 2.6 2.5 2 2 2 2
2 2 2 2 2 2 1 1 3 2 2 2 2 2 2 2 2 2 2 2 2 2
2 2 2 2 2 2 1 1
2 2 2 2 1 1 2 1 1 1 99 1 1 2 2 2 1
2 2 2 2 2 2 1 1 3 2 1.6 2 2 1 1 3 2 2 2 2 2 2
2 2 2 2 2 1 2 1 1 1 2 1 2 2
2 2 2 2 1 1 2 1 1 1 7 4 2 2 2 2
2 2 2 2 2 2 1 1 2 3 2 2 2 2 2
2 2 2 2 2 2 1 1 1 3 2 2 2 2 2 99 2 2 2 2 2 2
2 2 2 1 1 1 2 1 1 1 3 2 1 2 2 2
2 2 2 2 1 1 2 1 1 99 2 2 2 2 2 2
2 2 2 2 1 1 2 1 2 1 1 3 2 2 2 2 2
2 2 2 2 1 2 2 1 1 1 3 2 2 2 2 2
2 2 2 2 1 1 2 1 1 1 99 3 3 2 2 2 2
2 2 2 2 2 2 1 1 1 3 2 2 2 2 2
2 2 2 2 1 2 1 2 1 1 4.9 3.8 2
2 2 2 1 2 1 2 1 1 1 6.3 3.1 2 2 2 2
2 2 2 1 2 1 2 2 1 1 4.9 3.6 2 2 2 1 1 1.6 1.3 2 2 2 2
2 2 2 1 1 1 1 1 2 2 2 2 1 1 1 2 2 2 2
2 2 2 1 1 1 2 2 2 1 1 5.3 2.7 1 1 2 2
2 2 2 2 2 2 2 1 1 6 4 2 1 2 2
2 2 2 2 1 2 1 1 1 3 2 2 2 2 2 2
2 2 2 2 1 2 1 1 2 6 4 2 2 2 2
2 2 2 1 2 1 2 1 1 1 2 1 2 2 2 2 1 5 3 2 2 2 2
2 2 2 2 1 1 2 1 1 1 1 1 1.5 2 2 2 2 99 0.5 0.5 2 2 2 2
2 2 2 2 2 1 2 1 1 1 2 2 2 2 2 2
2 2 2 2 2 2 1 1 2 2 1.5 2 2 2 2
2 2 2 2 2 2 2 1 1 10.3 7.5 2
2 2 2 2 2 2 2 2 1 5.4 3.3 2 2 2 2
2 2 2 2 1 1 2 1 1 1 1.5 1.5 2 2 2 2 1 0.5 0.5 2 2 2 2
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rafluct radis rasin lano lalsize labsize latend lafluct ladis lasin rino rilsize ribsize ritend rifluct ridis risin lino lilsize libsize litend lifluct lidis lisin hb alc esr crp cd4 gotoevent
11.7 1805 50 63.9 2
12.3 1210 52 378 1
12.4 2695 32 3.14 999 1
12.2 44 3.35 523 2
2 2 2 9.8 1482 70 30.9 2
11.8 1587 39 16 1
13.2 27 46.7 1
9.6 664 50 1
15.7 946 42 34 181 2
10 2080 52 9.18 737 2
11.1 2231 8 3.14 732 2
7.7 768 69 76.3 528 2
14.2 3416 14 4.41 652 2
12.2 798 2
13.8 1824 17 3.14 662 2
12.9 1885 16 3.14 539 2
13 1430 10 3.14 2
11.3 1330 65 5.88 576
13.2 2075 50 10.4 756 2
14.2 1584 13 2
13.9 988 40 31.3 282 2
12.9 32 7.32 2
15.9 2349 4 3.14 878 2
15.7 2460 4 3.14 2
12.4 2052 32 8.57 919 2
9.7 276 72 58 129 2
13.2 1349 37 365 2
12.1 1216 291 2
2 2 2 1 1 1 2 2 2 2 12.7 1460 38 11.9 719 2
14.1 3294 14 3.63 1416 2
11.1 996 52 19.1 528 2
9.9 2923 47 6.69 931 2
12.2 1440 12 3.17 494 2
10.8 1860 2
15.7 2754 16 12.9 1320 2
8.5 672 2
9.6 300 10 57 250 2
13 2
12.9 752 45 99 2
12.4 1900 20 3.17 806 2
12.8 228 14 3.14 619 2
11.7 3330 36 9.4 1441 2
12.9 2750 30 13.2 838 2
12.8 992 31 15.1 414 2
10.8 2088 66 45.1 989 2
11.5 1632 14 17.2 601 2
9 1125 92 45.8 458 2
12.3 2522 7 9.26 958 2
10.1 1375 54 7.59 451 2
12.6 1562 63 34.6 2
12.3 1881 14 802 2
9.3 1271 80 37.7 2
9.8 2070 84 26.9 505 2
12.1 1136 23 19.8 383 2
11.2 45 11.8 2
2 2 2 15.4 1806 8 12.4 751 2
12.7 2233 45 12.4 537 2
10.8 1309 30 4.45 710 2
13.4 1170 42 8.98 2
11.7 1900 30 24.4 767 2
12.1 2622 37 3.02 1031 2
12.2 30 3.02 641 2
9.2 2832 10 3.14 1059 2
11.1 2438 45 19.2 905 2
10.3 2700 57 14.5 791 2
13.9 1624 19 699 2
11.9 1392 26 37.2 304 2
2 2 2 13.9 1344 16 62.9 359
12.7 1470 39 16.9 498 2
11.6 1488 44 3.02 805 2
114 
 
 
rcnos2 rclsizes2 rcbsizes2 rctends2 rcflucts2 rcdiss2 rcsins2 lcnos2 lclsizes2 lcbsizes2 lctends2 lcflucts2 lcdiss2 lcsins2 ranos2 ralsizes2 rabsizes2ratends2 raflucts2 radiss2 rasins2 lanos2 lalsizes2
1 1 1 2 2 2 2 1 3.2 3.1 2 1 2 2
1 5.5 4.5 1 1 1 1
2 3 4 1 2 2 2
1 4 5 2 1 2 2
1 4 4 1 2 1 1
1 8 6 2 1 1 1
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labsizes2latends2 laflucts2 ladiss2 lasins2 rinos2 rilsizes2 ribsizes2 ritends2 riflucts2 ridiss2 risins2 linos2 lisizes2 libsizes2 litends2 liflucts2 lidiss2 lisins2 afbs2 cultures2xperts2 rifrs2 sensits2 biopsys2 necrosiss2
2 2 2 1 1
2 2 1 2
2 2 1 2 1 1
2 2 2 1 2
2 2 2 1 1
2 2 1 2 1 1
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pilldayss2isoniazid1rifampici1pyrazin1 ethambuto1strepto1 vomits2 diarrs2 atts2 hbs2 alcs2 esrs2 crps2 cd4s2 fupeventevent progres dissem1 fluct dischar sinus hbevent alcevent esrevent crpevent cd4event
2
2
2
2
1 2
0 300 450 1500 800 2 2 2 14 1659 3 3.17 362
1 1 2 1 1 1 12.1 1920 10 4.9
0 300 450 1000 800 2 2 2 13 1995 27 26 1007
1 1 2 2 1 1 22 7.23 691
0 2 2 2 10.9 1488 78 25.9 745 2 1 1 2 2 2 1 1386 57 5.01 486
0 300 450 1500 800 2 2 2 10.3 2071 53 3.14 607 1
1 1 1 1 1 1 7.2 206 57 78
0 300 600 1500 1200 2 2 2 10.8 3132 24 15.7 1901
1
1
1
1
2
2
2
2
0 300 450 1250 1000 2 2 2 11.8 1131 35 69.8 352
1
2
2
2 1 1 2 1 2 2 14.3 1984 5 3.02
2
2
2
2
2
2
2
2
2
1
2
2
2
2
2
1
2
2
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
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eventsizebreadth cervical axillary inguinal othsite pilldaye isoniazid2rifampici2pyrazin2 ethambuto2strepto2 drugdosefollow rebiopsy rebiopsynoafbev cultureevxpertev rifrev sensitev biopsyev necrosisevomitev diarrev attev
3.5 1 2 2 0 300 450 1250 1000 1 1 2 2 2 2
4 4 1 2 2 0 300 600 1700 1400 1 1 2 3
3 2 1 2 2 300 600 1 1 2 2 1 2 1 1 2 2 2
7 1 2 2 300 450 1000 800 1 1 1 1 1 1 2 1 1 1 2 2 2
1 2 2 0 300 600 1500 1200 1 2 2 2 2
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fup2mnt progres2mdissem2mfluct2m dischar2msinus2m hb2m alc2m esr2m crp2m fup6mnt progres6mdissem6mfluct6m dischar6msinus6m hb6m alc6m esr6m crp6m outside cmc totdur surgtreatsurgproc steriod pentoxi conservatprogress dissemin prtime
2 2 2 2 2 2 4 42 2 2 2 2 2 2 14.2 2079 2 15 0 6 6
2 2 2 2 2 2 1 5 6 11
2 2 2 2 2 2 2346 33 3.14 1 10 10
2 2 2 2 2 2 12.9 1404 18 3.02 2 0
2 2 2 2 2 2 8 3.14 2 2 2 2 2 2 12.4 1680 6 3.03 5 10 15 1 Left Limited Neck Dissection2 2 2 1 2 5
2 2 2 2 2 2 17 5.58 2 2 2 2 2 2 27 6.57 9 9 2 2 1 1 2 2
1 8
1 2 2 2 2 2 2 15.5 1792 4 3.03 0 10 10 2 2 1 1 2 2
2 2 2 2 2 2 2 11.6 1406 67 12.5 3 9 12 1 Left Limited Neck Dissection2 1 2 1 2 2
2
3 15 18 1 Bilateral Limited Neck Dissection with excision of tuberculous sinuses1 1 2 1 1 4
2 2 2 2 2 2 7 5.21 2 2 2 2 2 2 10.6 2848 20 11.4 3 11 14 2 2 1 1 2 3
2 2 2 2 2 2 13.9 2 6
2 2 2 2 2 2 11.6 1988 3 3.02 2 2 2 2 2 2 11.2 1850 3 3.16 0 6 6
2 2 2 2 2 2 2432 18 5.25 2 2 2 2 2 2 6 6
2 2 2 2 2 2 12.9 1435 3.02 2 2 2 2 2 2 13.1 1470 14 3.03 7 7
2 2 2 2 2 2 11.4 1458 5 3.02 2 2 2 2 2 2 12.6 1564 3 7 7
2 2 2 2 2 2 12.4 1666 34 3.14 2 2 2 2 2 2 9 9
2 2 2 2 1 1 49 6.98 1 10 10
2 2 2 2 2 2 11.6 11764 48 3.29 2 2 2 2 2 2
2 2 2 2 2 2 14.4 9 9
2 2 2 2 2 2 27 4.21 1 9 9
2 2 2 2 2 2 16.2 2613 3 3.14 2 2 2 2 2 2 2535 4 3.02 7 7
2 2 2 2 2 2 14.7 3105 6 3.02 1 7 7
2 2 2 2 2 2 2 2 2 2 2 2 9 9
2 2 2 2 2 2 12.3 1404 21 3.14 2 2 2 2 2 2 16 16 1 Left Limited Neck Dissection2 1 2 1 1 5
2 2 2 2 2 1 13.2 5.12 2 4 9 13
2 2 2 2 2 2 14.4 2400 22 3.14 2 2 2 2 2 2 14.4 1892 18 5.47 9 9
2 2 2
2 2 2 2 2 2 2
2 2 2 2 2 2 13.1 2604 28 3.02 2 7
2 2 2 2 2 2 11.1 2952 25 3.16 2 2 2 2 2 2 19 4.87 9
2 2 2 2 2 2 10.4 22 2 2 2 2 2 2 14.7 1134 3 3.02 0 9 9
2 2 2 2 2 2 17 3.22 2 2 2 2 2 2 10 10
2 2 2 2 2 2 15 2592 17 11.3 2 2 2 2 2 2 15.3 3710 9 9.86 0 9 9
2 2 2 2 2 2 10.2 1170 24 10.2 2 0 11 11
2 2 2 2 2 2 7.8 702 2 2 2 2 2 2 11.6 1166 17 0 9 9
2 2 2 2 2 2 34 16.5 1
2 2 2 2 2 2 5 3.14 2 2 2 2 2 2 0 9 9
2 2 2 2 2 2 2 2 2 2 2 2 14.7 1925 7 3.02 0 8 8
2 2 2 2 2 2 12.6 2262 6 3.02 1
2 2 2 2 2 2 10.7 2275 10 3.02 2
2 2 2 2 2 2 12.3 2047 25 9.67 2
1
2 2 2 2 2 2 2
2 2 2 2 2 2 13 4.92 2 1
2
2 2 2 2 2 2 12.1 1760 8 6.13 2
2 2 2 2 2 2 13.5 17 2
2 2 2 2 2 2
1
2 2 2 2 2 2 9.4 1820 21 3.03 2
2 2 2 2 2 2 11.8 2310 45 5.66 2
1
2 2 2 2 2 2 2 2 2 2 2 2 38 8.17 0 9 9
2 2 2 2 2 2 15.4 2 2 2 2 2 2 0 9 9
2 2 2 1 2 2 40 12.5 2 2 2 2 2 2 61 15.5 10 12 22
2 2 2 2 2 2 12.6 2400 18 4.41 2
2 2 2 2 2 2 42 14.5 2
2 2 1 2 2 2 35 2
2 2 2 2 2 2 2
2 2 2 2 2 2 12.5 1728 29 2.49 2
2 2 2 2 2 2 10 3.14 2 2 2 2 2 2 11.2 3081 1 3.03 0 6
2 2 2 2 2 2 2
2 2 2 2 2 2 12.1 2961 22 18.9 2
2 2 2 2 2 2 2 2 2 2 2 2 13.3 1500 29 17 0 6 6
2 2 2 2 2 2 13.2 1848 16 3.03 2
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